Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.77)
# 3,328
Out of 5,114 analysts
42
Total ratings
45%
Success rate
0.4%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Buy | n/a | $48.18 | - | 5 | Sep 2, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $92.50 | +62.16% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $33.80 | +136.69% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $9.02 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $91.36 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $4.90 | +144.90% | 2 | Mar 7, 2023 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $48.09 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $4.16 | +741.35% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $136.06 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $854.99 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $48.61 | - | 4 | Feb 4, 2021 |
Sanofi
Sep 2, 2025
Upgrades: Buy
Price Target: n/a
Current: $48.18
Upside: -
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $92.50
Upside: +62.16%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $33.80
Upside: +136.69%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $9.02
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $91.36
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $4.90
Upside: +144.90%
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.09
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $4.16
Upside: +741.35%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $136.06
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $854.99
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $48.61
Upside: -